Canaccord Genuity Maintains Buy on TransMedics Gr, Raises Price Target to $169
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Jason Mills maintains a Buy rating on TransMedics Group (NASDAQ:TMDX) and raises the price target from $117 to $169.
August 01, 2024 | 2:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Jason Mills maintains a Buy rating on TransMedics Group and raises the price target from $117 to $169.
The raised price target from $117 to $169 by Canaccord Genuity indicates strong confidence in TransMedics Group's future performance. This is likely to positively impact the stock price in the short term as investors react to the bullish outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100